Factor XIII Val 34 Leu: a novel association with primary intracerebral hemorrhage.

BACKGROUND AND PURPOSE A common G-to-T point mutation (Val 34 Leu) in exon 2 of the alpha-subunit of the factor XIII is strongly negatively associated with the development of myocardial infarction. This result suggests that factor XIII Val 34 Leu is interfering with the formation of cross-linked fibrin. The role of factor XIII Val 34 Leu in the pathogenesis of cerebral infarction and primary intracerebral hemorrhage is unknown. METHODS Six hundred twelve patients with acute stroke, defined by World Health Organization criteria and cranial CT, and 436 age-matched control subjects free of cerebrovascular disease were genotyped for the factor XIII Val 34 Leu mutation. Venous blood was drawn for the determination of hemostatic variables and lipids. Factor XIII genotype was determined through a single-stranded conformational polymorphism technique and plasminogen activator inhibitor (PAI)-1 4G/5G promoter genotype by allele-specific polymerase chain reaction. RESULTS The mutation was more frequent in patients with primary intracerebral hemorrhage (n=62) (54.8%; P=.05) than in control subjects (41.7%) or in patients with cerebral infarction (n=529) (46.5%; P=.22). There was no relationship between PAI-1 levels and the PAI-1 4G/5G genotype. CONCLUSIONS There was a slightly higher incidence of factor XIII Val 34 Leu in patients with PICH. This may be related to impaired cross-linking of fibrin and/or coagulation proteins.

[1]  A. Carter,et al.  Association of a Common Polymorphism in the Factor XIII Gene with Myocardial Infarction , 1998, Thrombosis and Haemostasis.

[2]  A. Carter,et al.  Plasminogen Activator Inhibitor-1 (PAI-1) 4G/5G Promoter Polymorphism and Levels in Subjects with Cerebrovascular Disease , 1997, Thrombosis and Haemostasis.

[3]  M. Blombäck,et al.  Proneness to Formation of Tight and Rigid Fibrin Gel Structures in Men with Myocardial Infarction at a Young Age , 1996, Thrombosis and Haemostasis.

[4]  P. Grant,et al.  Environmental and Genetic Factors in Relation to Elevated Circulating Levels of Plasminogen Activator Inhibitor-1 in Caucasian Patients with Non-Insulin-Dependent Diabetes Mellitus , 1995, Thrombosis and Haemostasis.

[5]  L. Peltonen,et al.  Deficiency in the A-subunit of coagulation factor XIII: two novel point mutations demonstrate different effects on transcript levels. , 1994, Blood.

[6]  A. Carter,et al.  Polymorphisms of the Plasminogen Activator Inhibitor- 1 Gene in Type 1 and Type 2 Diabetes, and in Patients with Diabetic Retinopathy , 1994, Thrombosis and Haemostasis.

[7]  J. Manson,et al.  Prospective study of endogenous tissue plasminogen activator and risk of stroke , 1994, The Lancet.

[8]  E. Ernst,et al.  Fibrinogen and Viscosity as Risk Factors for Subsequent Cardiovascular Events in Stroke Survivors , 1992, Annals of Internal Medicine.

[9]  J. Bamford,et al.  Classification and natural history of clinically identifiable subtypes of cerebral infarction , 1991, The Lancet.

[10]  J Bamford,et al.  The frequency, causes and timing of death within 30 days of a first stroke: the Oxfordshire Community Stroke Project. , 1990, Journal of neurology, neurosurgery, and psychiatry.

[11]  A. Bloom Haemostasis and thrombosis , 1981 .

[12]  Y. Sakata,et al.  Cross-linking of alpha 2-plasmin inhibitor to fibrin by fibrin-stabilizing factor. , 1980, The Journal of clinical investigation.

[13]  Y. Sakata Cross-Linking of a2-Plasmin Inhibitor to , 1980 .

[14]  T W Meade,et al.  Haemostasis and thrombosis. , 1978, International journal of epidemiology.

[15]  S. Hatano,et al.  Experience from a multicentre stroke register: a preliminary report. , 1976, Bulletin of the World Health Organization.

[16]  J. Hermans,et al.  Effects of calcium ion and covalent crosslinking on formation and elasticity of fibrin cells. , 1975, Thrombosis research.